Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer. Final Protocol dated 2007-06-19, Protocol Amendment 1 dated 2007-08-06, Protocol Amendment 2 dated 2007-08-16, Protocol Amendment 3 dated 2007-10-31, Protocol Amendment 4 dated 2007-12-17, Protocol Amendment 5 dated 2008-04-14, Protocol Amendment 6 dated 2008-09-09, Protocol Amendment 7 dated 2009-04-15 The primary objective is to evaluate the efficacy of ABR-215050 vs. placebo in asymptomatic patients with metastatic CRPC, as measured by the proportion of patients who have not progressed at 6 months...

• Country None
• organs None
• Specialty None

10TASQ10 : Essai de phase 3 randomisé en double aveugle évaluant l’efficacité du tasquinimod, chez des patients ayant un cancer de la prostate métastatique résistant à la castration. [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité de l’adjonction du tasquinimod au traitement standard, chez des patients ayant un cancer de la prostate métastatique résistant à la castration. Les ...

• Country France
• organs Prostate
• Specialty Thérapies Ciblées

A phase II/III study on treatment with ABR-217620 combined with IFN-α vs. IFN-α alone in patients with advanced renal cell carcinoma Overall survival

• Country None
• organs None
• Specialty None

An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE). Final Protocol dated 2009-03-16. Protocol Amendment 1 dated 2009-10-13. Protocol Amendment 2 dated 2009-12-02 To assess changes in disease activity and biomarkers in patients with mild active SLE during treatment with ABR-215757.

• Country None
• organs None
• Specialty None

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod) To study changes in disease related biomarkers in patients with progressive SSc during treatment with ABR-215757

• Country None
• organs None
• Specialty None